ACHE and Alzheimer disease: More specific to AChE, however, randomized, placebo-controlled trials show that short-term donepezil-induced AChE inhibition (one year) in prodromal AD patients slows gray matter atrophy in the hippocampus [59], cortex [60], and basal forebrain [61].